Evaluating induction and maintenance treatment with MMX mesalazine for patients with mild-to-moderate ulcerative colitis

被引：0
|
作者：
Solomon, D. [1 ]
Abhyankar, B. [2 ]
Barrett, K. [2 ]
Karlstadt, R. [1 ]
机构：
[1] Shire Pharmaceut Inc, Wayne, PA USA
[2] Shire Pharmaceut Ltd, Basingstoke, Hants, England
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2010年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A90 / A90
页数：1
相关论文
共 50 条
  • [1] MMX mesalazine is well tolerated during 12 months' maintenance treatment of mild-to-moderate ulcerative colitis
    Kamm, M. A.
    Lichtenstein, G. R.
    Sandborn, W. J.
    Barrett, K.
    Joseph, R. E.
    [J]. GUT, 2007, 56 : A113 - A113
  • [2] Maintenance of clinical remission with MMX® mesalazine 2.4 g/day in patients with mild-to-moderate ulcerative colitis, irrespective of prior treatment
    Kane, S.
    Solomon, D.
    Palmen, M.
    Barrett, K.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A91 - A91
  • [3] MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis
    Sandborn, W.
    Kamm, M.
    Lichtenstein, G.
    Barrett, K.
    Joseph, R.
    [J]. INFLAMMATORY BOWEL DISEASES, 2008, 14 (01) : S24 - S24
  • [4] Methodological Approach to Mesalazine Treatment in Patients with Mild-to-moderate Ulcerative Colitis
    Agilli, Mehmet
    Dogan, Tolga
    Ergin, Giray
    [J]. INFLAMMATORY BOWEL DISEASES, 2015, 21 (08) : E14 - E15
  • [5] Reply to Methodological Approach to Mesalazine Treatment in Patients with Mild-to-moderate Ulcerative Colitis
    Pedersen, Natalia
    Munkholm, Pia
    [J]. INFLAMMATORY BOWEL DISEASES, 2015, 21 (08) : E15 - E16
  • [6] Symptom improvement after 1 weeks' treatment with MMX® mesalazine 2.4 g/day for induction of remission of mild-to-moderate ulcerative colitis
    Kane, S.
    Solomon, D.
    Palmen, M.
    Barrett, K.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A91 - A91
  • [7] Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study
    D'Haens, G.
    Hommes, D.
    Engels, L.
    Baert, F.
    Van der Waaij, L.
    Connor, P.
    Ramage, J.
    Dewit, O.
    Palmen, M.
    Stephenson, D.
    Joseph, R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (07) : 1087 - 1097
  • [8] Satisfaction with therapy among patients treated with MMX™ mesalamine for maintenance of remission in patients with mild-to-moderate ulcerative colitis
    Sandborn, W.
    Lichtenstein, G.
    Kamm, M.
    Barrett, K.
    Joseph, R.
    [J]. INFLAMMATORY BOWEL DISEASES, 2008, 14 (01) : S24 - S24
  • [9] Mesalazine granules promote disease clearance in patients with mild-to-moderate ulcerative colitis
    Kruis, Wolfgang
    Meszaros, Silke
    Wehrum, Sarah
    Mueller, Ralph
    Greinwald, Roland
    Nacak, Tanju
    [J]. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2023, 11 (08) : 775 - 783
  • [10] MMX® Mesalazine A Review of its Use in the Management of Mild to Moderate Ulcerative Colitis
    Yang, Lily P. H.
    McCormack, Paul L.
    [J]. DRUGS, 2011, 71 (02) : 221 - 235
12345